Form 4: Vigil Neuroscience Director Granted 5,000 Restricted Stock Units

Vigil Neuroscience, Inc. Director Suzanne Louise Bruhn was granted 5,000 Restricted Stock Units (RSUs) on May 22, 2025, as part of the company's 2021 Stock Option and Incentive Plan.

Summary

• Suzanne Louise Bruhn, a Director of Vigil Neuroscience, Inc. (VIGL), reported an acquisition of securities.
• The transaction occurred on May 22, 2025, and involved the acquisition of 5,000 shares of Common Stock.
• These shares represent Restricted Stock Units (RSUs) issued under the Issuer's 2021 Stock Option and Incentive Plan.
• Each RSU provides the contingent right to receive one share of the Issuer's Common Stock.
• The RSUs were acquired at a price of $0 per share, which is typical for equity grants.
• Following this transaction, Suzanne Louise Bruhn beneficially owns 5,000 shares directly.
• The shares are subject to a vesting schedule, which will occur upon the earlier of May 22, 2026, or the next annual meeting of the Issuer's stockholders.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects a standard and beneficial practice of aligning director interests with shareholders through equity compensation, without any negative implications reported in the filing.

Positives

• The grant of Restricted Stock Units (RSUs) to a director aligns management's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• Equity grants are a common method for attracting and retaining qualified directors and executives, signaling commitment to long-term value creation.

Negatives

• The shares are not immediately liquid as they are subject to a vesting period, meaning the director cannot sell them until the vesting conditions are met.

Future Outlook

The acquired Restricted Stock Units (RSUs) are scheduled to vest upon the earlier of May 22, 2026, or the next annual meeting of the Issuer's stockholders, indicating a future increase in the director's direct share ownership upon vesting.

Industry Context

The grant of Restricted Stock Units (RSUs) to a director is a standard practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to compensate board members and align their financial interests with the long-term performance of the company.

Comparison to Industry Standards

• The issuance of Restricted Stock Units (RSUs) as part of director compensation is a widely accepted practice across various industries, including biotechnology, aligning with common corporate governance standards.
• The vesting schedule, tied to a specific date or the next annual meeting, is a typical structure for such equity grants, comparable to practices observed in companies like Biogen Inc. or Moderna, Inc., which also utilize equity-based compensation plans for their non-employee directors.

Related Party Transactions

• The transaction involves the issuance of Restricted Stock Units (RSUs) to Suzanne Louise Bruhn, a Director of Vigil Neuroscience, Inc., which constitutes a related party transaction as it is compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial incentives with shareholder interests, potentially encouraging decisions that enhance long-term stock value.
• Employees: While not directly impacting employees, such compensation practices for directors are part of the overall corporate compensation strategy.

Next Steps

• The Restricted Stock Units (RSUs) will vest upon the earlier of May 22, 2026, or the next annual meeting of Vigil Neuroscience, Inc.'s stockholders, at which point they will convert into shares of Common Stock.

Key Dates

Keywords

Vigil Neuroscience, VIGL, Restricted Stock Units, RSU, Insider Transaction, Form 4, Director Compensation, Equity Grant, Stock Option Plan